These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23307040)

  • 1. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
    Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
    J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
    Lin SM; Yang SH; Liang CC; Huang HK
    Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
    Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
    Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
    Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
    BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
    Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
    Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton pump inhibitor use and the antifracture efficacy of alendronate.
    Abrahamsen B; Eiken P; Eastell R
    Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between proton pump inhibitor use and risk of fracture: A population-based case-control study.
    Kim JJ; Jang EJ; Park J; Sohn HS
    PLoS One; 2020; 15(7):e0235163. PubMed ID: 32730257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
    Park JH; Song YM; Jung JH; Han K
    Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.
    Lapi F; Cipriani F; Caputi AP; Corrao G; Vaccheri A; Sturkenboom MC; Di Bari M; Gregori D; Carle F; Staniscia T; Vestri A; Brandi M; Fusco V; Campisi G; Mazzaglia G;
    Osteoporos Int; 2013 Feb; 24(2):697-705. PubMed ID: 22618266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study.
    Lim SJ; Yeo I; Yoon PW; Yoo JJ; Rhyu KH; Han SB; Lee WS; Song JH; Min BW; Park YS
    Osteoporos Int; 2018 Nov; 29(11):2427-2435. PubMed ID: 30039251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
    Pouwels S; Lalmohamed A; Souverein P; Cooper C; Veldt BJ; Leufkens HG; de Boer A; van Staa T; de Vries F
    Osteoporos Int; 2011 Mar; 22(3):903-10. PubMed ID: 20585937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate use and subsequent hip fracture in South Korea.
    Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
    Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model.
    Park DH; Seo SI; Lee KJ; Kim J; Kim Y; Seo WW; Lee HS; Shin WG; Yoo JJ
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1534-1543. PubMed ID: 35501296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes.
    Chou YS; Jiang HJ; Chen CH; Ho PS; Lee TC
    Sci Rep; 2020 Aug; 10(1):14081. PubMed ID: 32826941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton-pump inhibitors and risk of fractures: an update meta-analysis.
    Zhou B; Huang Y; Li H; Sun W; Liu J
    Osteoporos Int; 2016 Jan; 27(1):339-47. PubMed ID: 26462494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
    Corley DA; Kubo A; Zhao W; Quesenberry C
    Gastroenterology; 2010 Jul; 139(1):93-101. PubMed ID: 20353792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study.
    Chiu HF; Huang YW; Chang CC; Yang CY
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1131-6. PubMed ID: 20872906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
    Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
    Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
    Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
    Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atypical subtrochanteric fractures after long-term bisphosphonate therapy].
    Czerwiński E
    Endokrynol Pol; 2011; 62 Suppl 2():42-5. PubMed ID: 22125022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.